Voriconazole-Induced QT Interval Prolongation: A Prospective Study
试验速览
- 阶段
- 不适用
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- QT interval prolongation
研究概览
简要总结
The antifungal voriconazole is effective for the treatment of invasive fungal infections in immunocompromised patients. A serious adverse reaction is QT interval prolongation, which may precede life-threatening arrhythmias, such as torsades de pointes. Although ventricular arrhythmias are mentioned as a possible adverse effect of voriconazole, thus far, the incidence and clear recommendations for QT follow-up have not been published. This prospective observational study aimed at describing the incidence of voriconazole induced- QT interval prolongation in the pediatric population and determine the risk factors for this phenomenon.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- — 至 20 Years(Child, Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •oral or IV treatment with voriconazole
排除标准
- •No data prior to initiation of voriconazole treatment on QT interval (baseline ECG)
- •Renal insufficiency or dialysis treatment
结局指标
主要结局
QT interval prolongation
时间窗: up to three months of treatment
次要结局
未报告次要终点
